• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Unveiling Cardiovascular Disparities in Lp(a)

Opinion
Video

Michael D. Shapiro, DO, and Jaime Murillo, MD, discuss the implications of high Lp(a) levels in the US population, racial disparities, and tailored interventions for high-risk groups.

This is a video synopsis/summary of an Insights involving Michael D. Shapiro, DO, and Jaime Murillo, MD.

Shapiro highlights findings from the US subgroup analysis of the global heritage study, emphasizing a notably high prevalence of elevated lipoprotein(a) (Lp[a]) levels among individuals with atherosclerotic cardiovascular disease (ASCVD). He stresses the relevance of measuring Lp(a) even in established ASCVD cases, as elevated Lp(a) provides additional risk information beyond standard cardiovascular factors, enabling more intensive low-density lipoprotein cholesterol lowering and prevention strategies.

Shapiro further addresses racial disparities, particularly among Black individuals, with half exhibiting elevated Lp(a) levels. This disparity increases Lp(a) attributable risk significantly, emphasizing the necessity of routine Lp(a) screening for both established ASCVD and at-risk individuals within this demographic. Additionally, Murillo emphasizes the impact on population health, especially among minority groups experiencing a surge in cardiovascular deaths, highlighting the need for targeted interventions.

Murillo stresses the importance of community engagement and partnership with scientists to address historical mistrust, advocating for comprehensive interventions targeting traditional risk factors and lifestyle modifications. This approach extends beyond Lp(a) measurement, focusing on holistic risk management within high-risk communities. These insights underscore the urgency of tailored interventions and routine Lp(a) screening to address disparities and mitigate cardiovascular risks among disproportionately affected populations.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Video 2 - "Payer Needs and Strategies for Evaluating and Covering PDTs"
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.